Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)

HIV-1 Infection Clinical Trial

Official title:

Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02440789
• Other study ID #: ACTG A5337
• Secondary ID: 2UM1AI068636
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 21, 2015
• Est. completion date: February 1, 2018

Study information

• Verified date: December 2019
• Source: AIDS Clinical Trials Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to find out about the safety of sirolimus in individuals with HIV infection who were also being treated with ART. The investigators wanted to learn whether sirolimus decreases inflammation and immune activation in the body; whether sirolimus changes the level of HIV in the participants' blood; and how sirolimus interacts with ART in the blood. Sirolimus is approved by the Food and Drug Administration (FDA) to prevent organ rejection in patients aged 13 years and older receiving kidney transplants. Sirolimus had also been used for the prevention of complications after stem cell transplants and as a treatment for certain kinds of cancers in HIV-infected patients.

Description:

The study was conducted with an initial lead-in period of 12 weeks where participants remained on ART, without study intervention. Samples were collected to define the pre-intervention steady-state of HIV, inflammation and immune activation parameters.

At week 12, sirolimus therapy was initiated for the planned 20 weeks of treatment. In order to achieve therapeutic levels, sirolimus therapy was initiated with lead-in dose of 0.025 or 0.05 mg/kg/day, depending on the ART regimen. Doses for each participant were then adjusted, based on trough blood sirolimus concentrations, to achieve target concentrations between 5 and 10 ng/mL. There were frequent initial visits for sirolimus trough concentration monitoring and potential dose adjustments, at weeks 12.5, 13, 13.5, 14, 14.5, 15, 15.5 and

16. Then visits occurred at weeks 18, 20, 24, 28 and 32. After the week 32 visit, the planned end of study treatment, there was an additional 12 weeks of post-sirolimus follow-up, with a final visit at week 44.

Study visits included physical examinations, clinical assessments, safety monitoring, and blood and oral swab collection. Anal swabs were collected at week 12 and 32. Samples were stored for subsequent protocol testing for the study outcomes.

In the primary analysis, the significance level was 0.05 for all analyses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: February 1, 2018
• Est. primary completion date: November 2, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV-1 infection

• On continuous ART for =24 months prior to study entry.

• CD4+ cell count =350 cells/mm^3

• Plasma HIV-1 RNA below the level of quantification for =24 months.

• White blood cell (WBC) =3000/mm^3

• Platelet count =125,000/mm^3

• Absolute neutrophil count (ANC) >1300/mm^3

• Aspartate aminotransferase (AST) <1.25 x upper limit of normal (ULN)

• Alanine aminotransferase (ALT) <1.25 x ULN

• Calculated creatinine clearance (CrCl) =60 mL/min

• Fasting or non-fasting triglyceride level =350 mg/dL

• Fasting or non-fasting LDL <160 mg/dL

• Urine protein to urine creatinine ratio =1 g/g from random urine collection

Exclusion Criteria:

• Serious illness requiring systemic treatment and/or hospitalization

• Documentation of any CDC Category C AIDS-indicator condition or oropharyngeal candidiasis (thrush)

• Intended modification of ART during the study.

• Latent tuberculosis (TB) infection

• TB disease within 48 weeks prior to study entry requiring treatment.

• History of active hepatitis B (HBV) infection.

• Hepatitis C virus (HCV) RNA-positive

• Previous myelodysplasia syndrome, lymphoproliferative disease, lung disease, malignancies, congestive heart failure, life-threatening fungal infection or herpes-zoster/varicella-zoster viral infection requiring treatment.

• Detectable Epstein-Barr virus (EBV) in blood

• Active infection other than HIV that required receipt of systemic antibiotic therapy by intravenous infusion

• History of major hypersensitivity reaction to macrolide drugs including angioedema, anaphylaxis, drug-induced dermatitis, or hypersensitivity vasculitis.

• Currently pregnant or breastfeeding, or planning to become pregnant prior to or during the study.

• Use of immunomodulators (eg, interleukins, interferons, and cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy.

• Active drug or alcohol use or dependence

• Vaccination within 14 days prior to study entry.

• On or planned to change to a PI-based ART or cobicistat-boosted regimen

• Anti-human papillomavirus (HPV) therapies

Related Conditions & MeSH terms

• HIV-1 Infection

Intervention

Drug:
• Sirolimus
Participants on a non-protease inhibitor (PI), non-non-nucleoside reverse transcriptase inhibitor (NNRTI) regimen, and for those on a non-PI, rilpivirine (RPV) based regimen received 0.025 mg/kg/day initial dose for 20 weeks. Participants on an NNRTI regimen with the exception of RPV received 0.05 mg/kg/day initial dose for 20 weeks.

Locations

Country	Name	City	State
United States	The Ponce de Leon Center CRS (5802)	Atlanta	Georgia
United States	Univ. of Cincinnati CRS (2401)	Cincinnati	Ohio
United States	Houston AIDS Research Team CRS (31473)	Houston	Texas
United States	Univ. of Miami AIDS CRS (901)	Miami	Florida
United States	Weill Cornell Uptown CRS (7803)	New York	New York
United States	31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS	Rochester	New York
United States	Washington University CRS (2101)	Saint Louis	Missouri
United States	801 University of California, San Francisco HIV/AIDS CRS	San Francisco	California
United States	University of Washington AIDS CRS (1401)	Seattle	Washington
United States	Whitman Walker Health CRS (31791)	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
AIDS Clinical Trials Group	National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Met the Study-defined Composite Safety Endpoint	The study-defined primary safety endpoint was a composite endpoint. A participant was considered to have met the endpoint if the participant 1) experienced a new Grade =3 Adverse Event (AE), including signs/symptoms, lab toxicity or clinical event, that was definitely, probably or possibly related to study treatment, as judged by the core team, or 2) had a change in CD4+ cell count ( confirmed >50% decline or to <300 cells/mm3) while on sirolimus. The screening visit occurred within 60 days of study entry.	Screening to study week 32 (week 20 of Sirolimus)
Primary	Efficacy - Immunologic: Frequency of HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma	Frequency of HIV-1 Gag-specific CD8+ T-cells by intracellular staining for IFN-gamma. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Primary	Efficacy - Immunologic: Change in HIV-1 Gag-specific CD8+ T-cells by Intracellular Staining for IFN-gamma	Change in HIV-1 Gag-specific CD8+ T-cells by intracellular staining for IFN-gamma (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Primary	Efficacy - Virologic: CD4+ T-cell-associated HIV-1 RNA	CD4+ T-cell-associated HIV-1 RNA. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Primary	Efficacy - Virologic: Change in CD4+ T-cell-associated HIV-1 RNA	Change in CD4+ T-cell-associated HIV-1 RNA (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Primary	Efficacy - Virologic: Plasma HIV-1 RNA by SCA	Plasma HIV-1 RNA by SCA	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Primary	Efficacy - Virologic: Change in Plasma HIV-1 RNA by SCA	Change in plasma HIV-1 RNA by SCA (week 32 measurement minus baseline measurement).; Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of CD4+ T-cell Counts	CD4+ T-cell counts. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in CD4+ T-cell Counts	Change in CD4+ T-cell counts (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 RNA Levels	HIV-1 RNA levels by conventional assay	weeks 0, 12, (pre-Sirolimus) 16, 24, 32 (4, 12, 20 weeks on Sirolimus) and 44
Secondary	Cell-associated HIV-1 DNA Levels in Total CD4+ Cells	HIV-1 DNA levels in CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in Cell-associated HIV-1 DNA Levels in Total CD4+ Cells	Change in HIV-1 DNA levels in CD4+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses	Frequency of HIV-1 Gag-specific CD107a+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific CD107a+ CD8+ T-cell Responses	Change in frequency of HIV-1 Gag-specific CD107a+ CD8+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses	Frequency of HIV-1 Gag-specific CD40L+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific CD40L+ CD8+ T-cell Responses	Change in frequency of HIV-1 Gag-specific CD40L+ CD8+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses	Frequency of HIV-1 Gag-specific IL-2+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific IL-2+ CD8+ T-cell Responses	Change in frequency of HIV-1 Gag-specific IL-2+ CD8+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses	Frequency of HIV-1 Gag-specific MIP1B+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific MIP1B+ CD8+ T-cell Responses	Change in frequency of HIV-1 Gag-specific MIP1B+ CD8+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cell Responses	Frequency of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific TNF-alpha+ CD8+ T-cell Responses	Change in frequency of HIV-1 Gag-specific TNF-alpha+ CD8+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific CD4+ T-cell by Intracellular Staining for IFN-gamma Responses	Frequency of HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific CD4+ T-cell by Intracellular Staining for IFN-gamma Responses	Change in HIV-1 Gag-specific CD4+ T-cells by intracellular staining for IFN-gamma (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific CD107a+ CD4+ T-cell Responses	Frequency of HIV-1 Gag-specific CD107a+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific CD107a+ CD4+ T-cell Responses	Change in frequency of HIV-1 Gag-specific CD107a+ CD4+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific CD40L+ CD4+ T-cell Responses	Frequency of HIV-1 Gag-specific CD40L+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific CD40L+ CD4+ T-cell Responses	Change in frequency of HIV-1 Gag-specific CD40L+ CD4+ T-cells (week 32 measurement minus baseline measurement).	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific IL-2+ CD4+ T-cell Responses	Frequency of HIV-1 Gag-specific IL-2+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific IL-2+ CD4+ T-cell Responses	Change in frequency of HIV-1 Gag-specific IL-2+ CD4+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific MIP1B+ CD4+ T-cell Responses	Frequency of HIV-1 Gag-specific MIP1B+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific MIP1B+ CD4+ T-cell Responses	Change in frequency of HIV-1 Gag-specific MIP1B+ CD4+ T-cells (week 32 measurement minus baseline measurement).	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cell Responses	Frequency of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in HIV-1 Gag-specific TNF-alpha+ CD4+ T-cell Responses	Change in frequency of HIV-1 Gag-specific TNF-alpha+ CD4+ T-cells (week 32 measurement minus baseline measurement).	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of %CD69+ CD4+ T-cells	Measurement of %CD69+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in of %CD69+ CD4+ T-cells	Change in of %CD69+ CD4+ T-cells (week 32 measurement minus baseline measurement).	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of %CD69+ CD8+ T-cells	Measurement of %CD69+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in of %CD69+ CD8+ T-cells	Change in of %CD69+ CD8+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of %Ki67+ CD4+ T-cells	Measurement of %Ki67+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in of %Ki67+ CD4+ T-cells	Change in of %Ki67+ CD4+ T-cells (week 32 measurement minus baseline measurement).	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of %Ki67+ CD8+ T-cells	Measurement of %Ki67+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in of %Ki67+ CD8+ T-cells	Change in of %Ki67+ CD8+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of %PD1+ CD4+ T-cells	Measurement of %PD1+ CD4+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in of %PD1+ CD4+ T-cells	Change in of %PD1+ CD4+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)
Secondary	Measurement of %PD1+ CD8+ T-cells	Measurement of %PD1+ CD8+ T-cells. Baseline is the mean of the two pre-Sirolimus measurements (study entry and study week 12).	At study weeks 0, 12, 16, 24, 32 (4, 12, 20 weeks on sirolimus) and 44
Secondary	Change in of %PD1+ CD8+ T-cells	Change in of %PD1+ CD8+ T-cells (week 32 measurement minus baseline measurement)	At study weeks 0, 12 and 32 (week 20 on Sirolimus)

External Links

•   DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 2.0, November 2014
•   Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual) Version 2.0 January 2010